Phase III Randomized Study of Ensartinib vs Crizotinib in Anaplastic Lymphoma Kinase (ALK) POSITIVE NSCLC Patients: eXalt3 Selvaggi, G., Wakelee, H. A., Mok, T., Wu, Y., Reck, M., Chiappori, A., Cicin, I., Lee, D. H., Breder, V., Fan, Y., Orlov, S., Poddubskaya, E., Wang, Z., Cheng, Y., Liu, Y., Wu, G., Mao, L., Zhou, J., Oertel, V., Horn, L., Liang, C. ELSEVIER SCIENCE INC. 2020: E41–E42

View details for Web of Science ID 000569266100003